Adagio Therapeutics has raised $80m funding to advance best-in-class antibodies to treat Covid-19. Credit: Gerd Altmann from Pixabay.

Adagio Therapeutics has raised $80m in funding to further advance best-in-class antibodies to both treat and protect against Covid-19.

The company plans to use the proceeds to advance its lead antibody candidate, ADG20, into clinical development early next year for the treatment of the disease.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ADG20 offers potential best-in-class treatment and durable protection against the SARS-CoV-2 virus that causes Covid-19 and future coronaviruses.

Previously known as Google Ventures, GV led the Series B funding round that involved participation from existing investors such as Polaris Partners, Mithril Capital, Fidelity Management & Research Company.

Other participants included OrbiMed, new investors, Population Health Partners and Omega Funds.

Adagio Therapeutics CEO Tillman Gerngross said: “The Adagio team has made extraordinary progress since launching the company in late June. In less than four months, we completed candidate optimisation, selected our lead antibody ADG20, established a manufacturing agreement to ensure global supply, and completed the production runs for ADG20 to be used in our upcoming clinical trials.

“Further, our team has received positive feedback from the FDA, allowing us to proceed to our first-in-human study in early 2021.”

Including the lead candidate ADG20, the company’s neutralising monoclonal antibodies can provide broad protection against SARS-CoV-2, SARS-CoV-1 and other coronaviruses monitored by virologists.

They are capable of binding to a highly conserved epitope on the spike protein of beta-coronaviruses that target human ACE2 and can reduce the potential risk of viral escape.

Adagio Therapeutics designed ADG20 to provide a combination of potency, durable protection, manufacturability, tolerability and affordability to patients and clinicians.

GV managing partner Krishna Yeshwant said: “As a preventative agent, ADG20 holds the promise of providing the efficacy necessary to deliver greater protection against Covid-19.”